Product Description
Trifluoperazine is an inexpensive accessible 'high potency' antipsychotic drug, widely used to treat schizophrenia or related psychoses. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14974020/)
Mechanisms of Action: D1 Antagonist,D2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Brazil | Canada | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Russia | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|